Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840735 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01840735: Completed Phase 1 study, sponsored by Gilead Sciences.
NCT01840735 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01840735, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will determine the safety, tolerability, and pharmacokinetics of a single dose of GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF.
Interventions
- DRUG Placebo
- DRUG GS-5737
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
What the finished NCT01840735 record still lists
NCT01840735 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01840735 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01840735 about?
NCT01840735 is a clinical study titled "Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF". This study will determine the safety, tolerability, and pharmacokinetics of a single dose of GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF.
What is the current status of trial NCT01840735?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01840735?
The interventions under investigation include: Placebo (DRUG), GS-5737 (DRUG).
Who is sponsoring clinical trial NCT01840735?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01840735's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia